These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 32855088)
21. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro. Shaughnessy CA; Zeitlin PL; Bratcher PE J Cyst Fibros; 2022 Jul; 21(4):637-643. PubMed ID: 35248469 [TBL] [Abstract][Full Text] [Related]
22. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series. Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610 [TBL] [Abstract][Full Text] [Related]
23. Ethical Dilemma: Elexacaftor-Tezacaftor-Ivacaftor or Lung Transplantation in Cystic Fibrosis and End-Stage Lung Disease? Breuer O; Shoseyov D; Koretz S; Alyan N; Reiter J; Cohen-Cymberknoh M; Wexler I; Kerem E Chest; 2022 Mar; 161(3):773-780. PubMed ID: 34506793 [TBL] [Abstract][Full Text] [Related]
24. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL; N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692 [TBL] [Abstract][Full Text] [Related]
25. Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy. Heo S; Young DC; Safirstein J; Bourque B; Antell MH; Diloreto S; Rotolo SM J Cyst Fibros; 2022 Mar; 21(2):339-343. PubMed ID: 34742667 [TBL] [Abstract][Full Text] [Related]
26. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351 [TBL] [Abstract][Full Text] [Related]
27. Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series. Gramegna A; De Petro C; Leonardi G; Contarini M; Amati F; Meazza R; Carugo S; Blasi F J Cyst Fibros; 2022 Sep; 21(5):885-887. PubMed ID: 35450770 [TBL] [Abstract][Full Text] [Related]
29. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis. McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711 [No Abstract] [Full Text] [Related]
30. Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype. Carnovale V; Iacotucci P; Terlizzi V; Colangelo C; Medio P; Ferrillo L; De Gregorio F; Francalanci M; Taccetti G; Buonaurio S; d'Ippolito M; Marsicovetere G; D'Andria M; Ferrara N; Salvatore D Respir Med; 2021; 189():106646. PubMed ID: 34673344 [TBL] [Abstract][Full Text] [Related]
31. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM; N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693 [TBL] [Abstract][Full Text] [Related]
32. Entering the era of highly effective modulator therapies. Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412 [TBL] [Abstract][Full Text] [Related]
33. Biliary disease and cholecystectomy after initiation of elexacaftor/ivacaftor/tezacaftor in adults with cystic fibrosis. Safirstein J; Grant JJ; Clausen E; Savant D; Dezube R; Hong G J Cyst Fibros; 2021 May; 20(3):506-510. PubMed ID: 32736949 [TBL] [Abstract][Full Text] [Related]
34. Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study. Salvatore D; Cimino G; Troiani P; Bignamini E; Esposito I; Leonetti G; Zanda M; Manunza D; Pepe A Pediatr Pulmonol; 2022 Sep; 57(9):2253-2256. PubMed ID: 35577767 [No Abstract] [Full Text] [Related]
36. Elexacaftor-tezacaftor-ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation. Gramegna A; Contarini M; Bindo F; Aliberti S; Blasi F Curr Opin Pharmacol; 2021 Apr; 57():81-88. PubMed ID: 33582393 [TBL] [Abstract][Full Text] [Related]
37. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Laselva O; Bartlett C; Gunawardena TNA; Ouyang H; Eckford PDW; Moraes TJ; Bear CE; Gonska T Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33303536 [TBL] [Abstract][Full Text] [Related]